The enactment of A10873 would have a substantial impact on state laws concerning health insurance. Specifically, it would modify existing regulations to mandate health plans to offer coverage for PAD, which is not uniformly covered in current policies. Given the prevalence and severity of PAD, this change is expected to facilitate easier access to critical medical services and potentially reduce future healthcare costs associated with untreated PAD complications. It reflects a growing trend toward improving healthcare accessibility through insurance coverage mandates.
Summary
Bill A10873 is aimed at amending the New York State insurance law to require that every health insurance policy, including those providing major medical or comprehensive-type coverage that offers prescription drug coverage, must also include coverage for peripheral artery disease (PAD). This condition is significant as it affects circulation and can lead to severe health complications. By including PAD coverage, the bill’s proponents aim to improve healthcare outcomes for affected individuals and provide them with necessary treatment options without facing excessive out-of-pocket expenses.
Contention
As with many healthcare-related bills, there may be points of contention surrounding A10873. Opponents might argue that mandating additional coverage could increase premiums for all policyholders, thereby making insurance less affordable overall. The discussion may also touch upon the balance between necessary healthcare provisions and the financial implications for insurance providers. Some stakeholders could express concerns about the potential administrative burdens this added requirement may impose on insurance companies, particularly in adjusting their policy frameworks and pricing models.
Requires health insurance plans to cover a medically necessary peripheral artery disease screening test for any at-risk individual; prohibits imposition of patient cost sharing for follow-up screenings or diagnostics.
Requires insurers to provide insurance coverage for treatment of rare diseases, life-threatening conditions or diseases, degenerative and disabling conditions, or diagnoses involving medically fragile children, by a provider of the patient's choice.